FACULTY

Melissa E. Badowski, PharmD, MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP
Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Chicago, IL
Relevant Disclosures:
No relevant financial relationships to disclose.

Meredith E. Clement, MD
Assistant Professor
Infectious Diseases
Louisiana State University Health Sciences Center
New Orleans, LA
Relevant Disclosures:
Advisor: Roche, ViiV
Independent Research Contractor (paid to institution): Gilead, Janssen, ViiV

Joseph J. Eron, Jr., MD
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC
Relevant Disclosures:
Consultant: Gilead, Merck, ViiV
Independent Research Contractor: Gilead, Janssen, ViiV

Chloe Orkin, MBBCh, FRCP
Consultant Physician, Barts Health NHS Trust
Clinical Lead for COVID 19 Research at Barts Health NHS Trust
Lead for HIV and HIV/Hep C Research
Athena Swan Chair, Queen Mary, University of London School of Medicine
London, United Kingdom
Relevant Disclosures:
Advisor: Gilead, GlaxoSmithKline, Janssen, Merck, ViiV
Speaker Contracted by Ineligible Company: Gilead, GlaxoSmithKline, Janssen, Merck, ViiV
Independent Research Contractor: Gilead, GlaxoSmithKline, Janssen, Merck, ViiV

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Explore how pre-exposure prophylaxis (PrEP) for HIV can successfully be implemented into clinical practice using an interprofessional approach.
• Assess the latest evidence regarding the selection of antiretroviral regimens in aging patients with HIV.
• Recognize the need for antiretroviral treatment regimens that improve patient adherence to therapy.
• Compare the use of 3-drug versus 2-drug antiretroviral regimens in terms of efficacy, safety, and meeting the needs of individual patients with HIV.

 Podcast 1

 Podcast 2

 Podcast 3

 Podcast 4

Back to Top